

NWT-03: The new approach for maintaining vascular health

Metabolic syndrome (MetS) is a cluster of common risk factors that raises the risk for heart disease and other health problems, such as diabetes and stroke. These include: large waistline, high triglyceride level, low HDL cholesterol level, high blood pressure, and high fasting blood sugar. One should have at least three metabolic risk factors to be diagnosed with metabolic syndrome (NHLBI, 2014). MetS has become a pandemic as a result of excess food consumption in relation to an unhealthy lifestyle. It precludes the fast growing problem of cardiovascular disease and type 2 diabetes. It is becoming increasingly accepted that, next to genes, nutrition plays the key role in the development of the risk factors associated with metabolic syndrome.

In the NWT-03 project, bioactive peptides are developed that can play a role in the prevention of a number of risk factors associated with metabolic syndrome.

In 2011, Newtricious started research with egg protein hydrolysates to demonstrate the positive effect on the maintenance of healthy blood vessels. Meanwhile, two clinical studies have been completed in healthy volunteers. Maastricht University and the University College Cork have played an important role in the preparation and conduct of the studies. The proof of principle study has been completed successfully. Subsequently, a pivotal dietary intervention study on vascular health maintenance has been completed. A second pivotal study is being prepared. The results will be used for writing a dossier aiming at health claim approvals with FDA, EFSA and other regulatory authorities.

Newtricious: Connecting science and well-being


Newtricious R&D is a Dutch Life Sciences company that develops the new generation of active food ingredients and specialized nutrition, which contribute to the maintenance of human health and well-being.


R&D and product-development activities are performed in close co-operation with development partners and executed in Newtricious-lead consortia of companies and knowledge institutes.

Via well-designed clinical studies that meet pharma standards, Newtricious is working towards securing regulatory health claims in almost all of the development programs. With a promising portfolio and solid IP in various health areas, such as obesity, metabolic syndrome, eye health, cardiovascular health, and diabetes, Newtricious' two leading development products are NWT-02 for eye health and NWT-03 for vascular health. The NWT-02 composition has been incorporated into the unique specialized food product MacuView. Recently, MacuView has been launched onto the Dutch market.

Newtricious' approach integrates early diagnostics, specialized nutrition and medical care and can help people to have more healthy years and improved quality of life.

Cardiovascular health





Specialized nutrition for **cardiovascular health**

Why NWT-03?

Maintaining cardiovascular health is a very important topic around the globe, which is becoming even more important because of the pandemics of obesity and diabetes. NWT-03 is a natural product based on an enzymatically hydrolyzed protein from egg white. It has promising effects on the maintenance of vascular health in in vitro experiments and in animal studies. In vitro effects include activity on ACE- and DPP-IV receptors, which are respectively associated with blood pressure and glycemic control. In diabetic rats, it was shown that the use of NWT-03 contributes to the maintenance of cardiovascular health and end organ health. Currently, a proof of principle study in humans has been completed successfully. Subsequently, a pivotal dietary intervention study on vascular health maintenance has been completed. A second pivotal study is being prepared. The results will be used for writing a dossier aiming at health claim approvals with FDA, EFSA and other regulatory authorities.

Ready to
License

